Artios Pharma
Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells
4
Funding Rounds
$420.2m
Money raised
Overview
Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells
-
Websites:
- Business model: B2B
- Headquarters: Cambridge, Cambridgeshire
- Social accounts:
Funding
Funding series
Funding Series Analysis
The company Artios Pharma has raised a total of $336.2m in funding over 4 rounds.
Key Insights:
- Artios Pharma Series C round, July 27, 2021: $153m
- Artios Pharma July 2021 Series C Funding Round: $150m
- Artios Pharma Series A round, September 2016: $33.2m
- Artios Pharma Limited funding round, August 2018: $84m
Artios Pharma Series C round, July 27, 2021
$153m
Artios Pharma July 2021 Series C Funding Round
$150m
Artios Pharma Series A round, September 2016
$33.2m
Artios Pharma Limited funding round, August 2018
$84m
Industries
Artios Pharma is active in the following industries: